SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update
SCYNEXIS, a clinical-stage biotech company, announced the initiation of a Phase 1 study for SCY-770, a novel AMPK activator aimed at treating Autosomal Dominant Polycystic Kidney Disease (ADPKD). Topline data for SCY-770 Phase 1 and SCY-247 Phase 1 IV formulation are expected in Q3 2026. The company is on track to initiate the Phase 2 proof-of-conc…